Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1671
This examiner grants 48% of resolved cases
Examiner Amelia Nicole Dickens is part of Tech Center 1600 and Art Unit 1645. The examiner has 126 resolved cases with an allowance rate of 47.6 percent. The median days to allowance for these cases is 1278. This data suggests a prosecution environment with the allowance rate and timeline documented here.
The interview lift is 21.1 percent. This positive lift indicates that conducting an interview increases the likelihood of allowance beyond the 47.6 percent baseline. Practitioners should consider this 21.1 percent lift as a strategy for overcoming rejections and moving the application toward a grant.
With 126 resolved cases, the examiner's performance is documented. The 47.6 percent allowance rate and 1278 median days to allowance provide benchmarks for applicants. The 21.1 percent interview lift shows that direct engagement with the examiner in Art Unit 1645 can provide a measurable boost to the chances of a successful outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18852236 | COMPOSITION CONTAINING BACILLUS AMYLOLIQUEFACIENS STRAIN FOR ENHANCING PLANT DISEASE RESISTANCE AND USE THEREOF | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18466984 | METHOD FOR PRODUCING FOREIGN PROTEIN USING E. COLI | Non-Final OA | KANEKA CORPORATION |
| 18016432 | RECOMBINANT MICROORGANISMS | Non-Final OA | The Regents of the University of California |
| 18574816 | BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF | Non-Final OA | Société des Produits Nestlé S.A. |
| 18286005 | ENCAPSULATED MICROBIAL COMPOSITIONS AND METHODS OF MAKING THE SAME | Final Rejection | Monsanto Technology LLC |
| 18665951 | PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18824806 | METHODS FOR DETERMINING ANTIBIOTIC SENSITIVITY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17335578 | METHODS FOR ASSESSING EFFICACY OF A DRUG IN VIVO BY MONITORING ADME PROTEINS IN EXTRACELLULAR VESICLES | Final Rejection | Purdue Research Foundation |
| 17788224 | PROCESS TO IDENTIFY CONSORTIA OF PROBIOTIC STRAINS SUITABLE FOR GLUTEN DEGRADATION | Final Rejection | Evonik Operations GmbH |
| 18167664 | Microbially Induced Inflammation Produces Changes in Distinct Healthy Tissues in Human Oral Cavity | Final Rejection | Colgate-Palmolive Company |
| 17775425 | A NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | Non-Final OA | Intervet Inc. |
| 17775428 | NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | Non-Final OA | Intervet Inc. |
| 18261226 | COMPOSITION FOR DECOMPOSITION OF TRYPSIN OR TMPRSS2 | Non-Final OA | Keio University |
| 18266167 | COMPOSITION COMPRISING BACTERIUM OF THE GENUS ACIDIPROPIONIBACTERIUM OR PROCESSED PRODUCT THEREOF | Non-Final OA | MEIJI CO., LTD. |
| 18161617 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC CONDITIONS | Non-Final OA | KEMIN INDUSTRIES, INC. |
| 18568661 | COMPOSITIONS AND METHODS FOR DETERMINING RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITORS (ICI), INCREASING EFFECTIVENESS OF ICI, AND TREATING CANCER | Final Rejection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN |
| 18576338 | BACTERIA STRAINS FOR TOPICAL SKIN CARE | Non-Final OA | LAC2BIOME S.R.L. |
| 18556680 | BACILLUS SUBTILIS FNFH_BS06 AND USE THEREOF | Final Rejection | ZHEJIANG OCEAN UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy